Four out of five Americans are affected

Four out of five Americans are affected with moderate-to-severe periodontitis and the market in the U.S. for treating these osseous defects is estimated at $50 million. For some time, periodontists have sought a breakthrough bone-replacement-graft technology that would repair the destruction of bone caused by periodontal disease. Now that technology is here.

Four out of five Americans are affected with moderate-to-severe periodontitis and the market in the U.S. for treating these osseous defects is estimated at $50 million. For some time, periodontists have sought a breakthrough bone-replacement-graft technology that would repair the destruction of bone caused by periodontal disease. Now that technology is here.

PepGen P-15 is said to be the first and only bioengineered bone-graft technology that facilitates bone repair in patients with periodontal disease. It promotes the attachment of reparative cells from surrounding tissues and facilitates bone repair for better defect fill, clinical attachment and predictability, while the synthetic peptide (P-15) eliminates immunological concerns associated with human allograft products.

PepGen P-15 is cost-effective for both professionals and patients because it reduces the need for retreatment while maintaining a balance to be autoclaved up to three times for subsequent procedures.

For additional information, contact CeraMed Dental at (800) 426-7836.

More in Science & Tech